NCT03096418View on ClinicalTrials.gov

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Breast Neoplasm Female
Interventions
DRUG

Paclitaxel

Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.

Trial Locations (1)

53792

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER